Article Summary 58
Strengths and limitations of this study: 59 -Registry recruitment status is often used to identify completed clinical trials, yet the reliability of this 60 information has not been previously assessed. 61 -The study involved comprehensive, independent literature searches by multiple investigators, including 62 a medical research librarian. 63 -This study design is unable to identify studies which were completed but not published. 64 Clinical trial registries play an essential role in helping to ensure the integrity of the published medical 67 literature. [1] When utilized appropriately by investigators and sponsors, registration helps to ensure 68 that a publically accessible trial record exists even when results are not published in a peer-reviewed 69 journal, and that published outcome measures are consistent with prospectively specified trial 70 outcomes. For these reasons, trial registries are a particularly important tool for systematic reviewers as 71 they attempt to identify both published and unpublished trial data in order to assess for the possibility 72 of publication bias. [ 
2] 73
Despite the critical importance of trial registration, compliance with requirements from both the 74
International Committee of Medical Journal Editors (ICMJE) and governmental regulators which 75 mandate the prospective registration of clinical trials has been imperfect.[3 4] Meta-researchers have 76
begun using data from ClinicalTrials.gov and other registries to identify these patterns of limited 77 compliance in order to publicize and monitor deficiencies. [ 
5 6] 78
Systematic reviewers and meta-researchers often limit registry searches to trials for which enrollment is 79 documented to have been completed in the registry.[5 7-13] Restricting reviews to completed studies 80 makes sense because these are the studies for which all the data is completed and for which the results 81 either are known or could be known. However, little is known about delays between the time of study 82 completion and the time that ClinicalTrials.gov is updated to reflect this completion, or the percentage 83 of completed trials which remain listed with an ongoing status in ClinicalTrials.gov indefinitely. If these 84 delays are significant or a large proportion of registry entries are never updated to reflect study 85 completion, then limiting registry searches to only entries with a completed registry status might miss 86 otherwise relevant trials. 87 The objective of this study is to quantify delays observed between the end of enrollment in registered 88 clinical trials, and the time that the registry entries are updated to reflect that enrollment has ended. 89
90

METHODS 91
Study selection and data collection 92
We searched ClinicalTrials.gov for phase 2-4 interventional studies registered between 01/01/2012 and 93 12/31/2015. From these potentially eligible trials (n=30,524) we randomly selected 500 studies for 94
analysis. Studies with a recruiting status of withdrawn were excluded, as this indicates that the study 95 was halted prior to enrolling any participants. For each included trial, we obtained information on study 96 phase, size, sponsor, participant demographics, and recruitment status as of January 1, 2017 directly 97 from ClinicalTrials.gov. 98
Dates for the following events were also recorded from ClinicalTrials.gov for each included trial: initial 99 registration, study start, and primary completion date (date on which primary outcome data for the last 100 trial participant were collected). When the primary completion date field was missing, we used the 101 study completion date (final date on which any trial data were collected). We considered trials with 102 recruitment statuses of either completed (study concluded normally) or terminated (recruitment 103 stopped prematurely and will not resume) to indicate that the study had ended and was unlikely to 104 resume activity. These trials were classified as concluded. We recorded the dates on which the registry 105 entries were updated to reflect that trials had concluded. Recruiting statuses which did not clearly 106 reflect that the trial had concluded were recruiting, enrolling by invitation, not yet recruiting, active not 107 recruiting, suspended, and unknown. Trials which were registered more than one month after the study 108 start date were considered retrospectively registered. 109 
Ongoing or Unknown Completion Status Trials 110
For studies which were scheduled to have been completed prior to January 2016 and did not have an 111 updated recruitment status indicating that they had concluded, we performed a comprehensive 112 literature search to identify published evidence that the trial might in fact have been completed. An 113 investigator first searched Medline via PubMed using trial registration number, keywords, condition 114 studied, intervention, trial title, and investigators' names for matching manuscripts. When the first 115 search identified no corresponding publication, a research librarian repeated this search using PubMed, 116
Embase, and Google Scholar. The final publication search occurred between January and February of 117
118
We assessed matches between registry entries and publications identified by this search strategy using 119 the following trial characteristics: study title, trial design, interventions, primary and secondary 120 outcomes, number of participants, recruitment dates, location, and funding sources. We did not 121 consider trials to be published if the publication did not include outcome data from the primary trial. For 122 example, trial protocols for ongoing trials were not considered evidence of trial completion. We did 123 consider published abstracts and presentations at scientific meetings to be evidence of trial completion, 124 and counted these as publications for this analysis. For the group of included trials with an ongoing or 125 unknown recruitment status listed in the registry, the primary outcome was the proportion of studies 126 with outcomes published in the medical literature. 127
Concluded Trials 128
For studies which were indicated to be concluded based on the recruitment status listed in 129 F o r p e e r r e v i e w o n l y 7 Secondary outcomes included the proportion of studies registered more than one month after study 133 initiation, and the proportion of studies registered after study completion. We also compared results 134 among subgroups based on trial phase, trial size, and funding source. 135
We calculated descriptive data for the primary and secondary outcomes. We also compared the median 136 time elapsed between the change in recruiting status and the time ClinicalTrials.gov was updated to 137 reflect this change between subgroups using Mann Whitney and Kruskal Wallis tests. Chi-square tests 138 were used to make comparisons between categorical variables. P values < 0.05 were considered 139 statistically significant. Statistical analyses were performed using PASW version 18.0 (IBM, Armonk, NY). 140
The dataset generated during the current study is available from the corresponding author on 141 reasonable request. 142
143
RESULTS
144
Of the 500 potentially eligible trials which were randomly selected for evaluation, 405 were eligible for 145 inclusion ( Figure 1 ). Phase 2, 3, and 4 trials were all well represented within the study sample, and the 146 majority of trials (53%) had received at least partial industry funding (Table 1) . A large proportion of 147 trials were registered retrospectively, more than one month after the study had started (39%). 148
Out of the 405 included trials, 273 (67%) were listed in ClinicalTrials.gov with a study status of 149 completed, and 40 (10%) had initiated enrollment but were terminated early. Ninety-two trials (23%) 150 had a recruitment status which indicated that trial activities were ongoing or that the study status was 151 unknown, including 22 (5%) listed as active or active but not recruiting, and 70 (17%) listed as having an 152 unknown recruiting status. Of these 92 trials with statuses in ClinicalTrials.gov indicating potentially 153 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   8 ongoing study activity, we identified a corresponding publication containing outcome data for 34 trials 154 (37%). 155
Among the trials with a completed or terminated status (n = 313), 2 were missing the study completion 156 date. Of the remaining 311 trials, the median delay between when a trial was completed and when 157
ClinicalTrials.gov was updated to reflect this change was 142 days (IQR 48-419), with a mean delay of 158 340 days. In 91 trials (29%) this delay was greater than 1 year, and in 39 trials (13%) the delay was 159 greater than two years (Figure 2 ). Eight trials had delays of more than five years. Retrospectively 160 registered trials had a median delay of 266 days (IQR 62-650 days) between trial completion and when 161 the registered recruitment status was updated, compared to a median of 116 days (IQR 38-260) for 162 prospectively registered trials (p < 0.001). Observed delays did not differ between trials according to 163 funding source or trial phase. 164
When considering all 405 included trials, 125 (31%) either had a listed recruitment status which was 165 incorrect (ie trial had been completed but was not listed as such) or had a delay of more than one year 166 between the time the study was completed and the time the recruitment status was updated. 167
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Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 7-8 (b) Report category boundaries when continuous variables were categorized Results: Among the 405 included trials, 92 had a registry status indicating that study activity was either 47 ongoing or the recruitment status was unknown. Of these, published results were available for 34 (37%). 48
Among the 313 concluded trials, the median delay between study completion and a registry update 49
reflecting that the study had ended was 141 days (IQR 48-419), with delays of over one year present for 50 29%. In total, 125 trials (31%) either had a listed recruitment status which was incorrect or had a delay 51 of more than one year between the time the study was concluded and the time the registry recruitment 52 status was updated. 53
Conclusions: At present, registry recruitment status information in ClinicalTrials.gov is often outdated 54 or wrong. This inaccuracy has implications for the ability of researchers to identify completed trials and 55 accurately characterize all available medical knowledge on a given subject. 56 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 analysis. Studies with a recruiting status of withdrawn were excluded, as this indicates that the study 98 was halted prior to enrolling any participants. Trials with a recruiting status indicating that recruitment 99 was ongoing and a planned Primary Completion Date (date that primary outcome data for the final 100 subject is collected) listed within ClinicalTrials.gov as being after 1/1/2016 were also excluded, as we 101 hypothesized that the yield from a publication search for trials completed after this date would be low. 102
For each included trial, we obtained information on study phase, size, sponsor, participant 103 demographics, and recruitment status as of January 1, 2017 directly from ClinicalTrials.gov. 104
Dates for the following events were also recorded from ClinicalTrials.gov for each included trial: initial 105 registration, study start, and primary completion date (date on which primary outcome data for the last 106 trial participant were collected). When the primary completion date field was missing, we used the 107 study completion date (final date on which any trial data were collected). We considered trials with 108 recruitment statuses of either completed (study concluded normally) or terminated (recruitment 109 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 stopped prematurely and will not resume) to indicate that the study had ended and was unlikely to 110 resume activity. These trials were classified as concluded. We recorded the dates on which the registry 111 entries were updated to reflect that trials had concluded from the History of Changes section within 112 each registry entry. Recruiting statuses which did not clearly reflect that the trial had concluded were 113 recruiting, enrolling by invitation, not yet recruiting, active not recruiting, suspended, and unknown. 114
Trials which were registered more than one month after the study start date were considered 115 retrospectively registered. 116
Ongoing or Unknown Completion Status Trials 117
For studies which did not have an updated recruitment status indicating that they had concluded, we 118 performed a comprehensive literature search to identify published evidence that the trial might in fact 119 have been completed. An investigator first reviewed the relevant ClinicalTrials.gov entry for relevant 120 publications and searched Medline via PubMed using trial registration number, keywords, condition 121 studied, intervention, trial title, and investigators' names for matching manuscripts. When the first 122 search identified no corresponding publication, a research librarian repeated this search using PubMed, 123
Embase, and Google Scholar. The final publication search occurred between January and February of 124
125
We assessed matches between registry entries and publications identified by this search strategy using 126 the following trial characteristics: study title, trial design, interventions, primary and secondary 127 outcomes, number of participants, recruitment dates, location, and funding sources. We did not 128 consider trials to be published if the publication did not include outcome data from the primary trial. For 129 example, trial protocols for ongoing trials were not considered evidence of trial completion. We did 130 consider published abstracts and presentations at scientific meetings to be evidence of trial completion, 131 and counted these as publications for this analysis. For the group of included trials with an ongoing or 132 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Concluded Trials 135
For studies which were indicated to be concluded based on the recruitment status listed in 136 ClinicalTrials.gov, the primary outcome was the amount of time elapsed between the primary 137 completion date listed in ClinicalTrials.gov and the date on which the Clinicaltrials.gov registry entry was 138 actually updated to indicate that the study had ended and was unlikely to resume activity. 139
Secondary outcomes included the proportion of studies registered more than one month after study 140 initiation, and the proportion of studies registered after study completion. We also compared results 141 among subgroups based on trial phase, trial size, and funding source. 142
We calculated descriptive data for the primary and secondary outcomes. We also compared the median 143 time elapsed between the change in recruiting status and the time ClinicalTrials.gov was updated to 144 reflect this change between subgroups using Mann Whitney and Kruskal Wallis tests. Chi-square tests 145 were used to make comparisons between categorical variables. P values < 0.05 were considered 146 statistically significant. Statistical analyses were performed using PASW version 18.0 (IBM, Armonk, NY). 147
The dataset generated during the current study is available from the corresponding author on 148 reasonable request. 149
150
RESULTS
151
Of the 500 potentially eligible trials which were randomly selected for evaluation, 405 were eligible for 152 inclusion (Figure 1 ). Phase 2, 3, and 4 trials were all well represented within the study sample, and the 153 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table 1) . A large proportion of 154 trials were registered retrospectively, more than one month after the study had started (39%). 155 3 Registration timing relative to recruitment could not be determined for one study 159 4 Listed recruitment status within ClinicalTrials.gov was incorrect or there was a delay of more than one 160 year between when the study concluded and when the registry recruitment status was updated to 161 reflect that recruitment ended. 162
163
Out of the 405 included trials, 273 (67%) were listed in ClinicalTrials.gov with a study status of 164 completed, and 40 (10%) had initiated subject recruitment but were terminated early. Ninety-two trials 165 (23%) had a recruitment status which indicated that trial activities were ongoing or that the study status 166 was unknown, including 22 (5%) listed as active or active but not recruiting, and 70 (17%) listed as 167 having an unknown recruiting status. Of these 92 trials with statuses in ClinicalTrials.gov indicating 168 potentially ongoing study activity, we identified a corresponding publication containing outcome data 169 for 34 trials (37%). 170
Among the trials with a completed or terminated status (n = 313), 2 were missing the study completion 171 date. Of the remaining 311 trials, the median delay between when a trial was completed and when 172 ClinicalTrials.gov was updated to reflect this change was 142 days (IQR 48-419), with a mean delay of 173 340 days. For 127 trials (41%), the recruitment status was changed promptly, with a delay of less than or 174 equal to 90 days. In 91 trials (29%) this delay was greater than 1 year, and in 39 trials (13%) the delay 175 was greater than two years ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Additionally, we performed a literature search to identify trials which were listed in the registry as being 231 ongoing, but which had actually been completed. It is likely that some additional trials were completed 232
but not yet published; our search would not have identified these trials. Similarly, our literature search 233 may have missed some trials. For these reasons, we may have underestimated the percentage of trials 234 which were completed without updating the registry's recruitment status. 235
CONCLUSIONS 236
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Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 7-8 (b) Report category boundaries when continuous variables were categorized Table 1 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses 17 Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses 8-9
Discussion
Key results 18 Summarise key results with reference to study objectives 9
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
10-11
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 11 Generalisability 21 Discuss the generalisability (external validity) of the study results 10
Other information
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